文︱陆弃 几周前，一场关于美国贸易政策的晚宴在纽约举行。讨论尚未深入，话题却迅速滑向中国。支持更强硬 立场的声音与主张传统路径的意见针锋相对，争论激烈，却并未形成共识。这一场景并不特殊，却具有 象征意味：在中美竞争被不断放大的背景下，美国政策圈与知识界对中国的认知裂缝愈发清晰。正是在 这样的氛围中，曾任美国财政部长顾问的史蒂文·拉特纳结束中国之行后，在《纽约时报》发表题为"我 刚从中国回来，我们美国没有赢下贸易战"的专栏。文章并未使用激烈措辞，却因其冷静与直白而引发 关注。 拉特纳的判断建立在亲历观察与长期投资经验之上。他描述的中国，并非抽象的宏观对手，而是一个在 人工智能、智能汽车、人形机器人、药物研发等领域展现出快速进展的现实经济体。这种观察本身并不 新鲜，真正值得审视的，是其所隐含的政策反思：当关税与出口管制被反复使用，却未能改变贸易结构 与技术演进轨迹，美国是否需要重新理解竞争的本质？ 贸易战的逻辑起点在于施压与调整，通过关税手段改变对方行为，重塑产业与供应链布局。然而，现实 反馈并未完全符合预期。中国继续维持全球最大出口国地位，贸易顺差创下历史纪录，显示出全球市场 对中国商品的依赖并未因关税显著逆转 ...

Group 1 - The core viewpoint of the article highlights that Jingtai Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across sample management, testing analysis, and data management [1] - The stock price of Jingtai Holdings increased by 4.52%, reaching HKD 11.8, with a trading volume of HKD 296 million [1] - The automated platform has been successfully delivered in high-value fields such as new drug development, chemical synthesis, and new material discovery [1] Group 2 - On February 5, Jingtai Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Jingtai Holdings' AI and robotics drug development platform with Weisheng Pharmaceutical's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]

Group 1 - The meeting between the Mayor of Nanjing, Li Zhongjun, and GE Healthcare's Global Executive Vice President, Song Weiqun, focused on enhancing collaboration in the medical technology sector [1] - GE Healthcare is recognized as a leading global medical technology company, with operations spanning medical imaging, digital healthcare, and drug development [1] - Both parties expressed commitment to leveraging their respective strengths to advance the nuclear medicine project and build a nuclear medicine ecosystem, aiming for high-quality development of Nanjing's biopharmaceutical industry [1]

Core Viewpoint - The article emphasizes the commitment to advancing research in the field of biomedicine, particularly focusing on neurodegenerative diseases and the development of innovative chiral nanomedicines [1] Group 1: Research Focus - The company aims to address cutting-edge challenges in the biomedicine sector, specifically targeting neurodegenerative diseases through new principles, mechanisms, and targets for intervention [1] - There is a strong emphasis on achieving breakthroughs in core technologies related to drug development [1] Group 2: Collaboration and Application - The company is actively responding to the "dual high synergy" mechanism by engaging deeply with clinical doctors and the industry [1] - The goal is to transition more research outcomes from the laboratory to clinical applications, ultimately benefiting the public [1]

Core Insights - The pharmaceutical industry faces a long-standing challenge of imbalance in input-output ratios, with new drug development taking an average of 12.5 years and costing up to $2.6 billion, while the success rate is below 10% [1] - Beijing Zheyuan Technology Co., Ltd. leverages artificial intelligence to empower pharmaceutical innovation, creating a computational medicine platform that serves as a "digital drug testing ground" [1] Group 1: Company Overview - Zheyuan Technology focuses on an "AI4S + disease" driven drug development path, integrating real patient data to build an integrated digital twin model of "human-disease-drug" [4] - The company has developed three core functional modules: new target discovery, virtual clinical trials, and precision medicine, which work synergistically to support drug innovation [4] Group 2: Technological Advancements - The digital twin model allows for precise identification of potential therapeutic targets, successfully leading to the development of a novel drug PR00012 for pancreatic cancer, with a unique mechanism of action [4] - The drug's development timeline from molecular design to IND approval was under two years, with clinical trials expected to begin in November 2024 [4] Group 3: Clinical Collaborations and Achievements - Zheyuan Technology collaborates with over 10 leading clinical centers in China on various pan-cancer clinical research projects and has received awards for disruptive technological innovation [5] - The company has completed a financing round of over 100 million yuan, which will be used for advancing core pipelines, global patent strategies, and platform upgrades [5] Group 4: Future Prospects - The company has identified over 200 potential high-value targets, each expected to develop into new drug IP assets worth over 10 billion [5] - Zheyuan Technology aims to enhance drug innovation success rates and improve global research efficiency and patient welfare through its "drug IP innovation factory" capabilities [5]

Core Insights - Insilico Medicine, a clinical-stage biopharmaceutical company driven by generative artificial intelligence, has announced a strategic drug development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center [1] - The partnership will leverage Insilico's proprietary Pharma.AI platform to develop small molecule inhibitors targeting specific pathways, focusing on the management of cardiovascular and metabolic diseases [1] - The total contract value exceeds HKD 931 million, which includes milestone payments for development and sales, as well as a share of future net sales [1] Company Summary - Insilico Medicine specializes in AI-driven drug discovery and development, particularly in the field of small molecule drugs for metabolic diseases [1] - Qilu Pharmaceutical Group will handle the subsequent development and commercialization of the drugs developed through this collaboration [1] Financial Summary - The collaboration agreement is valued at over HKD 931 million, indicating significant financial commitment and potential for revenue generation through milestone payments and sales sharing [1]

Group 1 - The Hang Seng Index fell by 0.1%, down 26 points, closing at 26,559 points, while the Hang Seng Tech Index decreased by 0.4% [1] - Baidu Group (09888) led blue-chip stocks with a 4% increase following the official release of its Wenxin large model version 5.0 [1] - Tianzuo Zhixin (09903) surged over 14%, reaching a new high since its listing, with plans to release a roadmap for its next three generations of GPGPU products on January 26 [1] - Minshi Group (00425) rose over 10%, benefiting from the increase in European electric vehicle production and actively entering humanoid robots and liquid cooling sectors [1] - Junda Co., Ltd. (02865) increased by over 14%, planning to raise funds through a share placement for the development of space photovoltaic battery products [1] - Yingshi Intelligent (03696) rose over 5%, achieving a new peak as its AI-enabled tumor drug development capabilities received further recognition [1] Group 2 - Jiantao Group's stock (01888) rose over 2%, with Goldman Sachs optimistic about the Chinese PCB and CCL industries [2] - Pacific Shipping (02343) increased by over 7%, reaching a new high as the BDI index climbed to a two-week high [3] - China Shipbuilding Defense (00317) rose over 3%, with its 2025 performance forecast meeting market expectations, likely benefiting from the integration of shipbuilding assets [4] - CNOOC Services (02883) increased by over 4%, converting $746 million in debt to equity to enhance its oil and gas business in Norway [5] - Kingsray Biotechnology (01548) fell over 6%, following a significant drop of over 11% in its joint venture Legend Biotech's stock price [6] - Nanshan Aluminum International (02610) dropped over 8% due to a 6.4% discount on a rights issue, raising net proceeds of HKD 1.99 billion [7] - New stock Longqi Technology (09611) debuted with a price of HKD 32.5, up 4.84% on its first day of trading [8]

Core Viewpoint - Chengdu XianDao is positioned as an innovative technology-driven biotechnology company, focusing on drug discovery and optimization through advanced platforms and technologies, including a large DNA-encoded small molecule library and AI integration [2][4][12]. Company Overview - Chengdu XianDao is a leading innovative biopharmaceutical company with the world's largest known DNA-encoded small molecule library, focusing on small molecule and nucleic acid drug discovery and optimization [2]. - The company has developed several core technology platforms, including DNA-encoded library (DEL) technology, fragment-based drug design (FBDD/SBDD), oligonucleotide-based drug development (OBT), and targeted protein degradation (TPD) [2][3]. Technological Capabilities - The company is constructing an automated closed-loop DEL+AI+automated DMTA (Design-Synthesis-Testing-Analysis) molecular optimization platform to accelerate the discovery and optimization of preclinical drug candidates [3]. - Chengdu XianDao's DEL technology allows for high-throughput screening of over 120 billion small molecules, significantly enhancing the efficiency of drug discovery [2][15]. Market Trends and Strategic Focus - The global biopharmaceutical industry is rapidly expanding, with a notable increase in innovative drug approvals. In 2024, the FDA approved 50 new drugs, with 32 being new chemical entities [7][8]. - Chengdu XianDao is strategically focusing on high-potential therapeutic areas such as oncology, inflammation, and autoimmune diseases, with the global oncology drug market projected to reach $304.8 billion by 2025 [8][9]. AI Integration in Drug Development - The company is leveraging AI to enhance drug discovery processes, focusing on building predictive models for compound affinity and optimizing molecular design through automated systems [12][13]. - However, challenges remain in fully integrating AI into drug development, with current applications primarily serving as research aids rather than providing systematic predictive outcomes [15][17]. Business Model and Growth Strategy - Chengdu XianDao aims to establish a sustainable and profitable business model by balancing its own drug pipeline with collaborative research projects, ensuring compliance with commercial rules and avoiding conflicts of interest with clients [6][7]. - The company emphasizes the importance of generating revenue growth to support its business expansion and technological advancements [7].

Core Viewpoint - Six new stocks will be listed on the Hong Kong Stock Exchange on December 30, marking a significant event as it is the first time since July 9 that six companies will ring the bell simultaneously [1] Group 1: Company Performance - AI-driven drug discovery and development company Insilico Medicine (3696.HK) saw a dark market increase of 53.26%, closing at HKD 36.86 [1] - Chinese digital twin technology company Wuyi Vision (6651.HK) experienced a dark market rise of 23.54%, closing at HKD 37.68 [1] - High-end domestic skincare brand Lin Qingxuan (2657.HK) reported a dark market increase of 18.75%, closing at HKD 92.35 [1] - Prefabricated steel structure service provider Meilian Holdings (2671.HK) had a dark market rise of 18.31%, closing at HKD 8.4 [1] - Data infrastructure and analytics company XunCe (3317.HK) saw a modest dark market increase of 2.04%, closing at HKD 48.98 [1] - Robotics company Woan Robotics (6600.HK) faced a dark market decline of 8.67%, closing at HKD 67.4 [1]

Core Viewpoint - The company emphasizes the importance of technological innovation and sustainable development in its operations [1] Group 1: Technological Innovation - The company plans to utilize AI technology to enhance innovation in drug development across various stages [1] Group 2: Sustainable Practices - The company's rice endosperm cell bioreactor is characterized as a plant-based manufacturing process, highlighting its environmentally friendly attributes [1]